| SUNDAY |
| 2:00 pm - 9:00 pm | Arrival and check-in |
| 6:00 pm | Dinner |
| 7:30 pm - 9:30 pm | Approaches to the Treatment of Anxiety and Depression in the 21st century |
| Discussion Leader: Al Robichaud (Wyeth) |
| 7:30 pm - 7:55 pm | Dave Wustrow (Pfizer)
"Gabapentin and Pregabalin. An Excursion from Neurology to Psychiatry" |
| 7:55 pm - 8:00 pm | Discussion |
| 8:00 pm - 825: pm | Ed Pierson (AstraZeneca)
"Structure-Activity Relationships of New Selective 5-HT1B Ligands. Potential Agents for Treatment of Anxiety and Depression." |
| 8:25 pm - 8:30 pm | Discussion |
| 8:30 pm - 8:55 pm | Dave Tupper (Eli Lilly)
"The Design and Synthesis of Novel Triple Reuptake Inhibitors for the Treatment of Depression " |
| 8:55 pm - 9:00 pm | Discussion |
| 9:00 pm - 9:25 pm | Leslie Street (Merck Sharp & Dohme, UK)
Targeting GABA-A Receptor Subtypes in the Brain: The Identification of Non-Sedating Anxiolytics |
| 9:25 pm - 9:30 pm | Discussion |
| MONDAY |
| 7:30 am - 8:30 am | Breakfast |
| 9:00 am - 12:30 pm | Understanding the HERG Channel and its Impact on Drug Discovery |
| Discussion Leader: John Lowe (Pfizer) |
| 9:00 am - 9:30 am | Mike Sanguinetti (Univ. of Utah)
"Features of the drug binding site of HERG revealed by study of mutant channels" |
| 9:30 pm - 9:40 pm | Discussion |
| 9:40 am - 10:10 am | Gea-Ny Tseng (Virginia Commonwealth University)
"Structure-Function Relationship of HERG's Outer Mouth: Implications in Drug Design" |
| 10:10 pm - 10:20 pm | Discussion |
| 10:20 am - 11:00 am | Coffee Break and Group Photo |
| 11:00 am - 11:30 am | Bernard Fermini (Pfizer)
"IKr/HERG inhibition in acquired Long QT Syndrome: impact on drug discovery and development" |
| 11:30 am - 11:40 am | Discussion |
| 11:40 am - 12:10 pm | Brian Springthorpe (AstraZeneca)
"hERG: one channel you don't want to tune in to!" |
| 12:10 pm - 12:20 pm | Discussion |
| 12:30 pm | Lunch |
| 1:30 pm - 6:00 pm | Free Time (either an organized MT. Kearsearge hike available, or a "shop n' drop" available) |
| 6:00 pm | Dinner |
| 7:30 pm - 9:30 pm | Winning the Battle of the Bulge? |
| Discussion Leader: Dave Rotella (Bristol-Myers Squibb) |
| 7:30 pm - 8:00 pm | Marc Reitman (Merck)
"Physiology of energy metabolism" |
| 8:00 pm - 8:10 pm | Discussion |
| 8:10 pm - 8:40 pm | Rustum Boyce (Chiron)
"Novel MC4R Agonists for the Treatment of Obesity" |
| 8:40 pm - 8:50 pm | Discussion |
| 8:50 pm - 9:20 pm | Henrik Sune Andersen (Novo Nordisk A/S, Denmark)
"Optimization of Oxalamic Acids as Potent Classical Competitive Inhibitors of Protein-Tyrosine Phosphatase 1B" |
| 9:20 pm - 9:30 pm | Discussion |
| 9:45 pm - 10:45 pm | Poster Session 1 & Social Hour
Discussion Leader: Pam Albaugh (Eli Lilly & Co., USA) |
| TUESDAY |
| 7:30 am - 8:30 am | Breakfast |
| 9:00 am - 12:30 pm | Novel Cancer Therapeutic Targets |
| Discussion Leader: George Hartman (Merck) |
| 9:00 am - 9:30 am | Mary Mader (Eli Lilly)
"Acyl Sulfonamide Anti Proliferatives: Structure-Activity Relationships for Novel Anti-Tumor Agents" |
| 9:30 pm - 9:40 pm | Discussion |
| 9:40 am - 10:10 am | Julian Adams (Millenium)
"Proteasome Inhibition in Cancer: The Discovery and Development of VELCADETM (PS-341)" |
| 10:10 pm - 10:20 pm | Discussion |
| 10:20 am - 10:50 am | Coffee Break |
| 10:50 am - 11:20 am | Laurent Hennequin (AstraZeneca)
"Discovery of new and highly potent c-Src inhibitors" |
| 11:20 pm - 11:30 am | Discussion |
| 11:30 am - 12:00 pm | Gustave Bergnes (Cytokinetics)
"Mitotic Kinesin-Targeted Agents!" |
| 12:00 pm - 12:10 pm | Discussion |
| 12:30 pm | Lunch |
| 1:30 pm - 5:00 pm | Free Time (organized annual East/West Softball game) |
| 5:00 pm - 6:00 pm | Poster Session A
Discussion Leader: Pam Albaugh (Eli Lilly) |
| 6:00 pm | Dinner |
| 7:30 pm - 9:30 pm | Novel Approaches to Pain Therapy |
| Discussion Leader: Chris Walpole (AstraZeneca) |
| 7:30 pm - 8:00 pm | Dave Cheshire (AstraZeneca)
"Orally active, selective iNOS inhibitors as novel drugs for pain and inflammation" |
| 8:00 pm - 8:10 pm | Discussion |
| 8:10 pm - 8:40 pm | Stéphane De Lombaert (Neurogen)
"Vanilloid Receptor (TRPV1) Antagonists" |
| 8:40 pm - 8:50 pm | Discussion |
| 8:50 pm - 9:20 pm | Sandra Filla (Eli Lilly)
"Potent and Selective Glu5 Kainate Receptor Antagonists for Treatment of Persistent Pain" |
| 9:20 pm - 9:30 pm | Discussion |
| 9:45 pm - 10:45 pm | Poster Session 2 & Social Hour
Discussion Leader: Pam Albaugh (Eli Lilly & Co., USA) |
| WEDNESDAY |
| 7:30 am - 8:30 am | Breakfast |
| 8:45 am - 9:00 am | Conference Business meeting |
| 9:00 am - 12:30 pm | Strategies Towards Novel Antithrombotics |
| Discussion Leader: Ruth Wexler (Bristol-Myers Squibb) |
| 9:00 am - 9:30 am | Jeff Weitz (Henderson Research Centre)
"Targets for New Antithrombotic Drugs" |
| 9:30 pm - 9:40 pm | Discussion |
| 9:40 am - 10:10 am | Ken Jacobson (NIH)
"P2 Nucleotide Receptors in Platelets as Antithrombotic Targets" |
| 10:10 pm - 10:20 pm | Discussion |
| 10:20 am - 10:50 am | Coffee Break |
| 10:50 am - 11:20 am | Mimi Quan (Bristol-Myers Squibb)
"The Discovery of BMS-561389 (DPC 906), a Highly Potent, Selective and Orally Bioavailable Factor Xa Inhibitor" |
| 11:20 am - 11:30 am | Discussion |
| 11:30 am - 12:00 pm | James Barrow (Merck)
"Discovery of Small Molecule TAFI Inhibitors as Novel Antithrombotics" |
| 12:00 pm - 12:10 pm | Discussion |
| 12:30 pm | Lunch |
| 1:30 pm - 5:00 pm | Free Time (organized annual Vice-Chair elect Golf Tournament) |
| 5:00 pm - 6:00 pm | Poster Session B
Discussion Leader: Pam Albaugh (Eli Lilly) |
| 6:00 pm | Dinner |
| 7:30 pm - 9:30 pm | Chemical Effectors in Target and Lead Discovery |
| Discussion Leader: William Michne (AstraZeneca) |
| 7:30 pm - 8:00 pm | Henry Pelish (Harvard)
"Secramine, Secretion, and the Cytoskeleton: Discovery through Chemical Genetics" |
| 8:00 pm - 8:10 pm | Discussion |
| 8:10 pm - 8:40 pm | Jonathan Ellman (UC Berkeley)
"Systems-Based Combinatorial Chemistry" |
| 8:40 pm - 8:50 pm | Discussion |
| 8:50 pm - 9:20 pm | Kenneth Comess (Abbott)
"Diversity Screening, Compound Validation, and Target Validation: Efficient Affinity-Based Screening Techniques to Enhance Lead Discovery" |
| 9:20 pm - 9:30 pm | Discussion |
| 9:45pm - | Planning Session for 2004 Conference
Discussion Leader: David Kimball [Lexicon Pharmaceuticals, USA] |
| THURSDAY |
| 7:30 am - 8:30 am | Breakfast |
| 9:00 am - 12:30 pm | Late Breaking Topics |
| Discussion Leader: Steve Street (Pfizer) |
| 9:00 am - 9:30 am | Kun Liu (Merck & Co., USA)
"Discovery of a Novel Series of Orally Active PPAR/ Dual Agonists for Treatment of Type 2 Diabetes and Dyslipidemia" |
| 9:30 am - 9:40 am | Discussion |
| 9:40 am - 10:10 am | Mike Wiley (Eli Lilly and Company, USA)
"LY517717: The Race to Replace Warfarin" |
| 10:10 am - 10:20 am | Discussion |
| 10:20 am - 10:50 am | Coffee Break |
| 10:50 am - 11:20 am | Heiner Glombik (Aventis DI&A, Germany)
"Non-absorbable Bile Acid Reabsorption Inhibitors for the Treatment of Hyperlipidemia" |
| 11:20 am - 11:30 am | Discussion |
| 11:30 am - 12:00 pm | Tony Wood (Pfizer, UK)
"CCR5 Antagonists for Treatment of HIV" |
| 12:00 pm - 12:10 pm | Discussion |
| 12:30 pm | Lunch |
| 1:30 pm - 6:00 pm | Free Time (coordinated trip to Guild of New Hampshire Craftsman Show at Mt. Sunapee State Park available) |
| 6:00 pm | Dinner |
| 7:30 pm - 9:30 pm | Chair's Talk |
| Discussion Leader: Phil Hipskind (Eli Lilly) |
| 7:30 pm - 8:30 pm | Barry M. Trost (Stanford)
"Synthetic Methodology and the Pharmaceutical Industry: A Retrospective Examination or Where Would We Be Without Recent Developments in Synthetic Methodology" |
| FRIDAY |
| 7:30 am - 8:30 am | Breakfast |
| 9:00 am | Departure |
